HAGHVERDI ET AL.
3 of 12
1
powder, yield: 60%. m.p.: 281–282 °C. H–NMR (CDCl3,
300 MHz): δ 7.01 (m, 2H), 7.26 (d, 1H, J = 8.37 Hz),
7.37 (t, 1H, J = 7.59 Hz), 7.64 (s, 1H), 7.74 (s, 1H), 8.04
(d, 1H, J = 7.7 Hz), 12.76 (s, 1H, N‐H), 13.26 (s, 1H, O‐
H). 13C–NMR (CDCl3, 75 MHz): 112.52, 117.23, 117.50,
117.65, 119.27, 123.07, 126.59, 132.05, 152.85, 157.87. IR
(KBr disc, cm−1): 3328, 3014, 2310, 1633, 1583, 1488,
1465, 1421, 1382, 1282, 1134, 1058, 844, 705. Anal. calcd
for C13H9N2OCl: C, 63.81, H, 3.68; N, 11.45. Found: C,
62.11; H, 3.38; N, 10.98%.
7.33 (t, 1H, J = 7.56 Hz), 7.40 (s, 2H), 8.00 (d, 1H, J =
7.69 Hz), 13.11 (s, 2H, N‐H, O‐H). 13C–NMR (CDCl3, 75
MHz): 19.96, 112.79, 117.08, 118.96, 125.88, 131.31,
131.48, 150.83, 157.92. IR (KBr disc, cm−1): 3257, 3124,
3049, 2970, 2858, 2241, 1637, 1589, 1488, 1461, 1417,
1384, 1257, 1130, 852, 675. Anal. calcd for C15H14N2O:
C, 75.63, H, 5.88; N, 11.76. Found: C, 74.29; H, 5.82; N,
11.42%.
The structure of the synthesized ligands is given in
Scheme 1. Except for HL4, these ligands had been synthe-
sized before.[9]
2.2.3 | 2‐(5‐methyl‐1H‐benzimidazol‐2‐yl)‐
phenol (HL3)
2.3 | Synthesis of the complexes C1–C5
2.3.1 | K2[Ni (HL1)2Cl2]2H2O (C1)
HL3 was prepared by using the same procedure as the syn-
thesis of HL1, except that 4‐methyl‐o‐phenylenediamine
was used instead of 1,2‐phenylenediamine. Cream brown-
ish powder, yield: 50%. m.p.: 255–256 °C. 1H–NMR
(CDCl3, 300 MHz): δ 2.42 (s, 3H, CH3), 7.01 (m, 2H),
7.08 (d, 1H, J = 8.16 Hz), 7.35 (t, 1H, J = 7.26 Hz),
7.43 (s, 1H), 7.53 (d, 1H, J = 8.13 Hz), 8.03 (d, 1H,
J = 7.71 Hz), 13.14 (s, 2H, N‐H, O‐H). 13C–NMR (CDCl3,
75 MHz): 21.29, 112.69, 117.15, 119.05, 124.29, 126.05,
131.54, 132.26, 151.40, 157.98. IR (KBr disc, cm−1): 3236,
3082, 3028, 2914, 2858, 2212, 1735, 1637, 1596, 1488,
1456, 1419, 1390, 1261, 1130, 846, 680. Anal. calcd for
C14H12N2O: C, 74.98, H, 5.35; N, 12.49. Found: C, 73.98;
H, 4.79; N, 12.15%.
A solution of HL1 (0.106 g, 0.5 mmol) and KOH (0.028 g,
0.5 mmol) in methanol was added to a solution of
.
NiCl2 6H2O (0.059 g, 0.25 mmol) in methanol. The color
change took place immediately. The resulting solution
was stirred for 24 h at room temperature. The completion
of the reaction was monitored by TLC. The precipitation
appeared in the resulting solution after a few days (by
slow evaporation of the solvent). The resulting precipita-
tion was separated by filtration, washed with diethyl ether
and dried in vacuum. Olive powder, yield: 50%. IR (KBr
disc, cm−1): 3419 (N‐H), 3058 (C‐H), 1623 (C = N), 1527
(C = C), 1255(C‐O), 486 (Ni‐O), 418 (Ni‐N). Anal. calcd
for C26H22N4O4K2Cl2Ni: C, 47.15, H, 3.32, N, 8.46, Ni,
8.86. Found: C, 48.00, H, 2.97, N, 7.60, Ni, 8.81%.
2.2.4 | 2‐(5,6‐Dichloro‐1H‐benzimidazol‐2‐
yl)‐phenol (HL4)
2.3.2 | K2[Ni (HL2)2Cl2]2H2O (C2)
HL4 was prepared by using the same procedure as the syn-
thesis of HL1, except that 4,5‐dichlorobenzene‐1,2‐
diamine was used instead of 1,2‐phenylenediamine. Pink
C2 was prepared in the same way as C1. Olive powder,
yield: 70.87%. IR (KBr disc, cm−1): 3433 (N‐H), 3176 (C‐
H), 1623 (C = N), 1560 (C = C), 1253(C‐O), 480 (Ni‐O),
418 (Ni‐N). Anal. calcd for C26H20N4O4K2Cl4Ni: C,
42.69, H, 2.73, N, 7.66, Ni, 8.03. Found: C, 44.62, H, 2.18,
N, 6.00, Ni, 7.70%.
1
powder, yield: 50%. m.p.: 327–328 °C. H–NMR (CDCl3,
300 MHz): δ 7.01 (m, 2H), 7.38 (t, 1H, J = 7.48 Hz),
7.87 (s, 2H), 8.05 (d, 1H, J = 7.66 Hz), 12.50 (s, 2H, N‐
H, O‐H). 13C–NMR (CDCl3, 75 MHz): 112.54, 116.08,
117.21, 119.36, 124.99, 127.00, 132.30, 133.53, 153.77,
157.71. IR (KBr disc, cm−1): 3332, 3097, 2320, 1637,
1598, 1487, 1444, 1419, 1371, 1298, 1132, 1097, 864, 740.
Anal. calcd for C13H8N2OCl2: C, 55.94, H, 2.89; N, 10.04.
Found: C, 55.68; H, 2.94; N, 9.61%.
2.2.5 | 2‐(5,6‐dimethyl‐1H‐benzimidazol‐2‐
yl)‐phenol (HL5)
HL5 was prepared by using the same procedure as the syn-
thesis of HL1, except that 4,5‐dimethylbenzene‐1,2‐
diamine was used instead of 1,2‐phenylenediamine.
1
Cream powder, yield: 50%. m.p.: 297–298 °C. H–NMR
(CDCl3, 300 MHz): δ 2.32 (s, 6H, CH3), 6.98 (m, 2H),
SCHEME 1 Structure of the synthesized ligands